Imprimis Pharmaceuticals Stock News

Harrow Health's (HROW) CEO Mark L. Baum on Q4 2021 Results - Earnings Call Transcript

The U.S. Food and Drug Administration ((FDA)) accepted Harrow Health''s (HROW) application seeking approval of AMP-100, an ocular surface anesthesia and intraoperative pain

Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.

Zacks Investment Research upgraded shares of Harrow Health (NASDAQ:HROW) from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $9.50 target price on the stock. According to Zacks, “Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, […]

Zacks Investment Research downgraded shares of Harrow Health (NASDAQ:HROW) from a buy rating to a hold rating in a research note released on Thursday morning, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, [] The post Harrow Health (NASDAQ:HROW) Downgraded by Zacks Investment Research appeared first on ETF Daily News .

Harrow Health (NASDAQ:HROW) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm currently has a $10.00 target price on the stock. Zacks Investment Research‘s target price points to a potential upside of 15.21% from the […]

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation EyePoin

Zacks Investment Research downgraded shares of Harrow Health (NASDAQ:HROW) from a buy rating to a hold rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield []

Select Medical (SEM) is focused on making strategic acquisitions to boost its business through inorganic growth.

Price T Rowe Associates Inc. MD cut its holdings in shares of Harrow Health, Inc. (NASDAQ:HROW) by 13.2% during the second quarter, HoldingsChannel.com reports. The fund owned 10,700 shares of the companys stock after selling 1,626 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in Harrow Health were worth $99,000 as of []

Acadia Healthcare Company (ACHC) expects to take on Orlando Health South Seminole Hospital's management responsibilities of the behavioral health program.

Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.

Harrow (HROW) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tren